August 13, 2019 / 5:18 AM / 4 days ago

BRIEF-Basilea Starts Phase 1/2 Study With Derazantinib In Urothelial Cancer

Aug 13 (Reuters) - BASILEA PHARMACEUTICA AG:

* BASILEA STARTS PHASE 1/2 STUDY WITH DERAZANTINIB IN UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below